Letter challenges claims of safe elective neck irradiation omission in pN0 oral cavity cancer

A methodological critique questions whether favorable regional control after postoperative neck RT omission establishes oncological safety without nodal dosimetry or comparative data.

KEY POINTS

  • This letter to the editor critically examines a previously published retrospective study by Mirallié and colleagues evaluating postoperative radiotherapy limited to the primary tumor bed in pT3–T4 pN0 oral cavity squamous cell carcinoma after neck dissection. The original study reported 96% regional control, with only three nodal recurrences, all associated with extensive local relapse, and no isolated neck failures.
  • The authors argue that the original single-center, noncomparative design cannot establish noninferiority of primary-site-only PORT against conventional postoperative treatment including elective neck volumes. The reported regional control estimate had a 95% CI of 87.5–98.6%, leaving substantial uncertainty regarding the true regional failure risk.
  • Adequacy of surgical nodal treatment was partly defined by retrieval of at least 18 lymph nodes, but the letter emphasizes that nodal count alone cannot verify complete removal of all anatomically relevant drainage levels. The original cohort included 43 patients undergoing ipsilateral dissection and 34 undergoing bilateral dissection, meaning contralateral pN0 status was not pathologically established for every patient.
  • The central dosimetric concern is that omission of an elective nodal CTV does not necessarily mean zero dose to the neck. Irradiation of the oral cavity primary tumor bed may expose adjacent first-echelon nodal levels, particularly levels IB and IIA, but the original study did not report level-specific mean dose, D95 or low- and intermediate-dose exposure.
  • The letter also identifies an apparent inconsistency between reported five-year outcomes: disease-free survival was 79.2% and overall survival 77.6%, despite definitions under which every death should count as a disease-free survival event. This discrepancy requires verification of endpoint definitions, event coding or reported estimates rather than immediate assumption of a clinical effect.
  • Prognostic modeling was based on relatively few events, including 16 recurrences and three regional failures, making extensive multivariable analyses vulnerable to overfitting. Additionally, the original study did not systematically assess xerostomia, dysphagia, fibrosis, lymphedema or quality of life, so the presumed toxicity benefit of omitting elective nodal irradiation was not directly demonstrated.
  • The authors recommend future studies incorporating predefined noninferiority criteria, side- and level-specific surgical documentation, nodal dose-volume analysis, standardized surveillance and patient-reported outcomes. Their position is that elective neck irradiation omission may be reasonable in carefully selected patients but should remain an individualized multidisciplinary decision rather than a universally validated de-escalation strategy.

CLINICAL TAKEAWAY

Favorable regional control following omission of postoperative elective neck irradiation is encouraging, but it does not establish oncological equivalence when patient selection, surgical extent and incidental nodal radiation exposure remain incompletely characterized. This letter reinforces the importance of distinguishing elective target omission from actual nodal dose reduction and of requiring comparative oncological and toxicity data before broader adoption.

SOURCE

Head & Neck

Browse more research Suggest a correction